Vistagen Therapeutics, Inc.

We are a late clinical-stage biopharmaceutical company focused on developing and commercializing a new class of non-systemic intranasal product candidates called pherines. These pherines are designed to activate nose-to-brain neurocircuits by binding to peripheral receptors in human nasal chemosensory neurons, without requiring systemic absorption or uptake into the brain to achieve therapeutic benefits. Our neuroscience pipeline includes five clinical-stage pherine product candidates, each with a novel mechanism of action and positive clinical data in their targeted indications. Our most advanced intranasal pherine product candidate is fasedienol, which is being investigated in our U.S. registration-directed PALISADE Program for the acute treatment of social anxiety disorder (SAD). In August 2023, we reported positive topline results from our PALISADE-2 Phase 3 trial of fasedienol for the acute treatment of SAD. The PALISADE Program also includes ongoing PALISADE-3 and PALISADE-4 Phase 3 trials, designed similarly to PALISADE-2, and a small exploratory Phase 2 repeat dose study (the Repeat Dose Study). The FDA has granted Fast Track designation for fasedienol for the acute treatment of SAD.